Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
First received: February 10, 2004
Last updated: January 15, 2013
Last verified: January 2013

RATIONALE: Drugs used in chemotherapy such as epothilone D work in different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well epothilone D works as second-line therapy in treating patients with advanced or metastatic refractory colorectal cancer.

Condition Intervention Phase
Colorectal Cancer
Drug: epothilone D
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study Of KOS-862 (Epothilone D), Administered Intravenously Weekly For 3 Weeks Every 4 Weeks, In The Second-Line Treatment Of Patients With Advanced Or Metastatic Colorectal Carcinoma (CRC)

Resource links provided by NLM:

Further study details as provided by Memorial Sloan Kettering Cancer Center:

Study Start Date: October 2003
Primary Completion Date: September 2004 (Final data collection date for primary outcome measure)
Detailed Description:



  • Determine the antitumor activity of epothilone D as second-line treatment, in terms of objective response rate, in patients with advanced or metastatic refractory colorectal cancer.


  • Determine the safety of this drug in these patients.
  • Determine the response duration in patients responding to treatment with this drug.
  • Determine time to tumor progression and overall survival in patients treated with this drug.
  • Correlate efficacy and safety with plasma concentrations of this drug and its major metabolites in these patients.

OUTLINE: This is an open-label, multicenter study.

Patients receive epothilone D IV over 90 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 19-69 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum
  • Evidence of at least 1 site of unidimensionally measurable disease by radiography or physical examination
  • Failed 1 prior treatment with a fluoropyrimidine in combination with either irinotecan OR oxaliplatin for advanced or metastatic disease
  • No known CNS metastases



  • 18 and over

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified


  • Hemoglobin ≥ 9 g/dL
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3


  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • AST and ALT ≤ 2.5 times ULN (5 times ULN if hepatic metastases are present)
  • Alkaline phosphatase ≤ 5 times ULN


  • Creatinine ≤ 1.5 times ULN


  • No New York Heart Association class III or IV congestive heart failure
  • No QTc > 450 msec for males or > 470 msec for females
  • No personal or family history of congenital long QT syndrome


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception
  • No pre-existing neuropathy grade 2 or greater
  • No documented grade 3 or 4 hypersensitivity reaction to prior therapy containing Cremophor
  • No infection requiring parenteral or oral anti-infective treatment
  • No altered mental status or psychiatric condition that would preclude giving informed consent
  • No other medical condition that would preclude study participation
  • No other malignancy within the past 5 years except cured basal cell skin cancer, carcinoma in situ of the cervix or bladder, or stage T1 or T2 prostate cancer with a prostate-specific antigen < 2 ng/mL


Biologic therapy

  • No concurrent sargramostim (GM-CSF)
  • No concurrent routine prophylactic use of filgrastim (G-CSF)


  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy and recovered

Endocrine therapy

  • Not specified


  • At least 3 weeks since prior radiotherapy and recovered


  • At least 3 weeks since prior surgery and recovered


  • More than 3 weeks since prior investigational agents (therapeutic or diagnostic)
  • No other concurrent therapy for advanced or metastatic colorectal cancer
  • No other concurrent investigational drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00077259

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Study Chair: Leonard B. Saltz, MD Memorial Sloan Kettering Cancer Center
  More Information

ClinicalTrials.gov Identifier: NCT00077259     History of Changes
Other Study ID Numbers: 03-113  MSKCC-03113  ROCHE-NO17320 
Study First Received: February 10, 2004
Last Updated: January 15, 2013
Health Authority: United States: Federal Government

Keywords provided by Memorial Sloan Kettering Cancer Center:
recurrent colon cancer
recurrent rectal cancer
stage III colon cancer
stage III rectal cancer
stage IV colon cancer
stage IV rectal cancer
adenocarcinoma of the colon
adenocarcinoma of the rectum

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases
Antimitotic Agents
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on May 01, 2016